Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)

The "Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification" is a grant opportunity that does not allow for clinical trials. This Funding Opportunity Announcement (FOA) is designed to offer significant support in the early phases of translational research. The aim is to help identify a lead series of compounds that could potentially be developed into therapeutic agents for the treatment of heart, lung, blood, and sleep diseases and disorders.

This FOA is just one part of the larger Catalyze innovation grants, which are focused on advancing projects until they reach a point where they're ready for the NHLBI Catalyze Preclinical program. Alternatively, these projects could also attract independent support from other federal entities or private partners. This support would aid in the preclinical stage of optimization and further development of therapeutic agents.